OTLK Outlook Therapeutics, Inc.
Company Analysis
Latest News
FDA Accepts BLA Resubmission for Wet AMD Drug, Sets July 29 PDUFA Date
Outlook Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted Biologics License Application (BLA) for ONS-5010...
🟢 OUTLOOK THERAPEUTICS INC is trading 6.6% up today after FDA appeal win for ONS-5010 and price target hike
OUTLOOK THERAPEUTICS INC is trading at $1.30 (up 6.6%) after a key FDA appeal win that enables the resubmission of its Biologics License Application (BLA) for...
🟢 OUTLOOK THERAPEUTICS INC is trading 6.6% up today after FDA appeal win and price target hike
• The company announced a significant regulatory update, with the FDA granting its appeal following a Formal Dispute Resolution process, paving the way for a...
Outlook Therapeutics Target Hiked to $10, Fueled by EU Drug Approval
Ascendiant Capital maintained its Buy rating for Outlook Therapeutics on June 11, 2026. The firm increased its price target to $10.00 from $6.00. This...
🟢 OUTLOOK THERAPEUTICS INC is trading 18.2% up today on analyst upgrade and positive FDA momentum
OUTLOOK THERAPEUTICS INC is trading 18.2% up at $1.30 following a significant price-target hike from Ascendiant Capital and continued positive momentum from...
🟢 OUTLOOK THERAPEUTICS INC is trading 10.91% up today after Ascendiant Capital raised its price target to $10
OUTLOOK THERAPEUTICS INC is trading at $1.22 (+10.91%) in after-hours action following a significant price-target increase and continued market momentum. •...
Ascendiant's $10 Target on a Sub-Dollar Stock: Is Outlook Therapeutics a Regulatory Lottery Ticket or a Real Turnaround?
Shares of Outlook Therapeutics surged 8.1% to $0.96 on June 11 after Ascendiant Capital analyst Edward Woo raised his price target from $6 to $10 — implying...
🟢 OUTLOOK THERAPEUTICS INC is trading 12.9% up today after Ascendiant Capital raised its price target to $10
OUTLOOK THERAPEUTICS INC is trading 12.9% up at $1.00 after Ascendiant Capital reiterated its Buy rating and significantly raised its price target. -...
🟢 OUTLOOK THERAPEUTICS INC is trading 8.1% up today after Ascendiant Capital raised its price target to $10
OUTLOOK THERAPEUTICS INC is trading 8.1% up at $0.96 today after Ascendiant Capital reiterated its Buy rating and raised its price target to $10.00. • The new...